Date: 2016-03-31
Type of information: R&D agreement
Compound: monoclonal antibodies
Company: Fusion Antibodies (UK) MAB Discovery (Germany)
Therapeutic area: Technology - Services
Type agreement: R&D
Action mechanism: monoclonal antibody
Disease:
Details: * On March 31st 2016, Fusion Antibodies, a UK-based contract research organisation and MAB Discovery, an antibody discovery company, announced their intention to enter into a research and licence agreement in the field of monoclonal antibodies. Within the scope of this collaboration, Fusion Antibodies will apply its proprietary CDRx™ Multiplex platform to humanize therapeutic antibodies selected and produced by MAB Discovery. MAB Discovery will provide high-quality humanized antibodies ready for further development to potential partners.
Financial terms:
Latest news:
